Back to top
more

Intellia Therapeutics (NTLA)

(Real Time Quote from BATS)

$26.34 USD

26.34
557,926

-0.08 (-0.30%)

Updated Jul 26, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -10.53% and 5.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA

by Zacks Equity Research

Intellia Therapeutics' (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, gets Regenerative Medicine Advanced Therapy designation for the treatment of hereditary angioedema.

Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Janux Therapeutics, Inc. (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Intellia Therapeutics, Inc. (NTLA) points to a 145.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.

Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) third-quarter 2022 loss is narrower than expected, while sales miss estimates.

Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance

by Zacks Equity Research

Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022

AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.

Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Intellia (NTLA) Reports Positive Results for CRISPR Candidates

by Zacks Equity Research

Intellia Therapeutics (NTLA) reported positive interim results for its CRISPR candidates being evaluated to treat transthyretin (ATTR) amyloidosis and treating hereditary angioedema (HAE).